Hypertension in Pregnancy 

About: Hypertension in Pregnancy is an academic journal published by Informa. The journal publishes majorly in the area(s): Preeclampsia & Pregnancy. It has an ISSN identifier of 1064-1955. Over the lifetime, 1148 publications have been published receiving 23941 citations.

The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP)

Abstract: (2001). The Classification and Diagnosis of the Hypertensive Disorders of Pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP) Hypertension in Pregnancy: Vol. 20, No. 1, pp. ix-xiv.

Subclassification of Preeclampsia

Abstract: Preeclampsia is a heterogeneous disorder, and as with other diseases (e.g., type I and type II diabetes), progress in the understanding of this disorder would be assisted greatly if subtypes could be characterized. We suggest that a first step would be to subdivide preeclampsia into early‐onset disease ( 34 + 0 weeks').

Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy

Abstract: A Working Group on Research in Hypertension in Pregnancy was recently convened by the National Heart Lung and Blood Institute to determine the state of knowledge in this area and suggest appropriate directions for research. Hypertensive disorders in pregnancy, especially preeclampsia, are a leading cause of maternal mortality worldwide and even in developed countries increase perinatal mortality five-fold. Much has been learned about preeclampsia but gaps in the knowledge necessary to direct therapeutic strategies remain. Oxidative stress is a biologically plausible contributor to the disorder that may be amenable to intervention. Hypertension that antedates pregnancy (chronic hypertension) bears many similarities to hypertension in nonpregnant women but the special setting of pregnancy demands information to guide evidence based therapy. The recommendations of the Working Group are to attempt a clinical trial of antioxidant therapy to prevent preeclampsia that is be complemented by mechanistic research to increase understanding of the genetics and pathogenesis of the disorder. For chronic hypertension clinical trials are recommended to direct choice of drugs, evaluate degree of control and assess implications to the mother and fetus. Recommendations to increase participation in this research are also presented.

Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States.

Abstract: Objectives: This study was to report the incidence of severe maternal morbidity associated with hypertensive disorders of pregnancy in the United States. Study Design: We used data from the National Hospital Discharge Survey, a nationally representative sample of discharge records, from 1988 to 1997. The database consisted of approximately 300,000 deliveries, which represented 39 million births during the 10‐year period. Results: The overall incidence of hypertensive disorders in pregnancy was 5.9% [95% confidence interval (CI): 5.2 to 6.5%]. Eclampsia was reported at 1.0 per 1000 deliveries (95% CI: 0.8 to 1.2). The incidence of eclampsia, severe preeclampsia, and superimposed preeclampsia remained unchanged during the 10‐year period. Women with preeclampsia and eclampsia had a 3‐ to 25‐fold increased risk of severe complications, such as abruptio placentae, thrombocytopenia, disseminated intravascular coagulation, pulmonary edema, and aspiration pneumonia. More than half of women with preeclampsia and e...

Lipid peroxidation in pregnancy

Abstract: Lipid peroxides and oxygen radicals are highly reactive and very damaging compounds. In normal pregnancy lipid peroxides increase, but antioxidants also increase to offset their toxic actions. However, this is not the case in preeclampsia. In women with preeclampsia, circulating levels of lipid peroxides are increased, but net antioxidant activity is decreased as compared to normally pregnant women. A source of circulating levels of lipid peroxides in pregnancy is the placenta because the placenta produces and secretes lipid peroxides, and lipid peroxide levels decrease after delivery of the placenta. Other sources are activated neutrophils, radical-initiated propagation, and self-propagation. Although some lipid peroxides are unstable, those present in oxidized low-density lipoproteins have a half-life of 3 h in die circulation and so function as circulating compounds. In preeclampsia, placental production of lipid peroxides is significantly increased, and this is correlated with significantly increased ...